Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | SCD | O00767 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20351812 | 1.00 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3FFAR1GRIN1 | |
| SCHEMBL18610914 | 0.80 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3FFAR1GRIN1 | |
| SCHEMBL18610909 | 0.80 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3FFAR1GRIN1 | |
| SCHEMBL20351811 | 0.79 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3FFAR1GRIN1 | |
| SCHEMBL20333529 | 0.79 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3FFAR1GRIN1 | |
| SCHEMBL19527586 | 0.77 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3FFAR1GRIN1 | |
| SCHEMBL20329796 | 0.77 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3GRIN1GRIN2B | |
| SCHEMBL20329798 | 0.76 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3FFAR1GRIN1 | |
| SCHEMBL19308484 | 0.76 | SCD (0.42) | SLC6A4SLC6A2SLC6A3SCDCYP2D6 | |
| SCHEMBL20064287 | 0.76 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3FFAR1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200262818-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262818-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | SLC6A4 4471/4885SLC6A2 4407/4885SLC6A3 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.